

PROVINCIAL FUNDING SUMMARY

Midostaurin (Rydapt) for Systemic Mastocytosis (pCODR 10193)

pERC Recommendation: Do not reimburse

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: April 20, 2020

This information is current as of June 1, 2020.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Under provincial consideration		
AB	Under provincial consideration		
SK	Under provincial consideration		
MB	Under provincial consideration		
ON	Under provincial consideration		
NS	Under provincial consideration		
NB	Under provincial consideration		
NL	Under provincial consideration		
PEI	Under provincial consideration		

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.